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During 1996–1997, a new Vibrio vulniﬁ  cus biotype 3, 
which  caused  severe  soft  tissue  infection  after  ?  shbone 
injury, emerged in Israel. We conducted a follow-up study 
from 1998 through 2005 to assess changing trends, out-
comes, and molecular relatedness of the implicated strains. 
A total of 132 cases (71% con?  rmed and 29% suspected) 
of V. vulniﬁ  cus biotype 3 infection were found. Most infec-
tions (95%) were related to percutaneous ?  sh exposure, 
mainly tilapia (83%) or common carp (13%). Bacteremia, al-
tered immune status, and history of ischemic heart disease 
were identi?  ed as independent risk factors for death, which 
reached a prevalence of 7.6%. Pulsed-?  eld gel electropho-
resis patterns of strains from 1998 through 2005 and from 
1996 through 1997 showed a high degree of homogeneity 
and were distinct from those of V. vulniﬁ  cus biotype 1. Infec-
tions caused by V. vulniﬁ  cus biotype 3 continue to affect the 
public’s health in Israel. 
V
ibrio vulniﬁ  cus, a gram-negative bacterium of the fam-
ily Vibrionaceae, is a worldwide inhabitant of salt wa-
ter (1–3). V. vulniﬁ  cus biotypes 1 and 2 are capable of caus-
ing severe human infection, including necrotizing fasciitis 
and septicemia; the death rate is substantial (4–6). Persons 
with chronic liver disease, particularly liver cirrhosis, are 
more prone to developing infection and at greatest risk for 
an adverse outcome (7,8). Other predisposing factors are 
iron overload and hemochromatosis and immunosuppres-
sion caused by steroid treatment, malignancy, HIV infec-
tion, renal failure, and organ transplantation (1,9,10).
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Learning Objectives
Upon completion of this activity, participants will be able to:
List the predisposing factors for infections caused by  •  Vibrio vulniﬁ  cus biotypes 1 and 2.
Identify the differences between infections caused by  •  V. vulniﬁ  cus biotypes 1 and 2 and biotype 3.
Describe the types of ? sh associated with  •  V. vulniﬁ  cus biotype 3 infection.
Describe the mortality associated with  •  V. vulniﬁ  cus biotype 3 infection.
List the predictors of mortality in  •  V. vulniﬁ  cus biotype 3 infection.
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1. Which of the following is least 
likely to be a predisposing factor for 
infections caused by Vibrio vulniﬁ  cus
biotypes 1 and 2?
A.   Anemia
B.   Organ transplantation
C.   HIV infection
D.   Chronic liver disease
2. Illness caused by V. vulniﬁ  cus
biotype 3 is best distinguished from 
that caused by biotypes 1 and 2 by 
which of the following?
A.   Method of transmission
B.   Genetic features
C.   Geographic distribution
D.   All of the above
3. Which of the following is the primary 
ﬁ  sh involved in V. vulniﬁ  cus biotype 3 
infection?
A.   Gray mullet
B.   Tilapia
C.   Salmon
D.   Sea bass
4. Which of the following best 
describes the mortality associated 
with V. vulniﬁ  cus biotype 3 infection as 
reported in Israel?
A.   1.0%
B.   2.3%
C.   5.2%
D.  7.5%
5. Which of the following is least likely 
to be an independent predictor of 
mortality for V. vulniﬁ  cus biotype 3 
infection?
A.   Bacteremia
B.   Ischemic heart disease
C.   Sex
D.   Altered immune status
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3. The content learned from this activity will impact my practice.
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